145 related articles for article (PubMed ID: 28157069)
1. Delayed de-induction of CYP2C9 compared to CYP3A after discontinuation of rifampicin: Report of two cases
.
Shibata S; Takahashi H; Baba A; Takeshita K; Atsuda K; Matsubara H; Echizen H
Int J Clin Pharmacol Ther; 2017 May; 55(5):449-452. PubMed ID: 28157069
[TBL] [Abstract][Full Text] [Related]
2. Rifampicin-warfarin interaction leading to macroscopic hematuria: a case report and review of the literature.
Martins MA; Reis AM; Sales MF; Nobre V; Ribeiro DD; Rocha MO; Ribeiro AL
BMC Pharmacol Toxicol; 2013 May; 14():27. PubMed ID: 23641931
[TBL] [Abstract][Full Text] [Related]
3. Variations in prothrombin time-international normalized ratio caused by drug-drug interaction in patients receiving warfarin: A retrospective observational study.
Shiraishi C; Hirai T; Fujita S; Dohi K; Iwamoto T
Int J Clin Pharmacol Ther; 2023 Apr; 61(4):139-147. PubMed ID: 36633369
[TBL] [Abstract][Full Text] [Related]
4. S-Warfarin Limited Sampling Models to Estimate Area Under the Concentration Versus Time Curve for Cytochrome P450 2C9 Baseline Activity and After Induction.
Chang AT; Bertino JS; Nafziger AN; Kashuba AD; Turpault S; Lewis LD; Ma JD
Ther Drug Monit; 2016 Jun; 38(3):383-7. PubMed ID: 26818625
[TBL] [Abstract][Full Text] [Related]
5. Difficulties in anticoagulation management during coadministration of warfarin and rifampin.
Lee CR; Thrasher KA
Pharmacotherapy; 2001 Oct; 21(10):1240-6. PubMed ID: 11601670
[TBL] [Abstract][Full Text] [Related]
6. Effect of rifampicin on the pharmacokinetics of imatinib mesylate (Gleevec, STI571) in healthy subjects.
Bolton AE; Peng B; Hubert M; Krebs-Brown A; Capdeville R; Keller U; Seiberling M
Cancer Chemother Pharmacol; 2004 Feb; 53(2):102-6. PubMed ID: 14605865
[TBL] [Abstract][Full Text] [Related]
7. Cytochrome P450 3A Induction Predicts P-glycoprotein Induction; Part 2: Prediction of Decreased Substrate Exposure After Rifabutin or Carbamazepine.
Lutz JD; Kirby BJ; Wang L; Song Q; Ling J; Massetto B; Worth A; Kearney BP; Mathias A
Clin Pharmacol Ther; 2018 Dec; 104(6):1191-1198. PubMed ID: 29569712
[TBL] [Abstract][Full Text] [Related]
8. Effect of rifampicin on the pharmacokinetics of lenvatinib in healthy adults.
Shumaker RC; Aluri J; Fan J; Martinez G; Thompson GA; Ren M
Clin Drug Investig; 2014 Sep; 34(9):651-9. PubMed ID: 25022720
[TBL] [Abstract][Full Text] [Related]
9. Describing the profile of patients on concurrent rifampin and warfarin therapy in western Kenya: a case series.
Maina MW; Pastakia SD; Manji I; Kirui N; Kirwa C; Karwa R
Drugs R D; 2013 Sep; 13(3):191-7. PubMed ID: 23982688
[TBL] [Abstract][Full Text] [Related]
10. Effects of folic acid supplementation on the pharmacokinetics and anticoagulant effect of warfarin: an open-label, prospective study of long-term administration in adults.
Muszkat M; Bialer O; Blotnick S; Adar L; Xie HG; Ufer M; Cascorbi I; Caraco Y
Clin Ther; 2010 Feb; 32(2):347-56. PubMed ID: 20206792
[TBL] [Abstract][Full Text] [Related]
11. Probable warfarin and dapsone interaction.
Truong T; Haley J
Clin Appl Thromb Hemost; 2012; 18(1):107-9. PubMed ID: 21890570
[TBL] [Abstract][Full Text] [Related]
12. Pharmacogenetic differences between warfarin, acenocoumarol and phenprocoumon.
Beinema M; Brouwers JR; Schalekamp T; Wilffert B
Thromb Haemost; 2008 Dec; 100(6):1052-7. PubMed ID: 19132230
[TBL] [Abstract][Full Text] [Related]
13. Pharmacokinetic/pharmacodynamic drug-drug interactions of avatrombopag when coadministered with dual or selective CYP2C9 and CYP3A interacting drugs.
Nomoto M; Zamora CA; Schuck E; Boyd P; Chang MK; Aluri J; Siu YA; Lai WG; Yasuda S; Ferry J; Rege B
Br J Clin Pharmacol; 2018 May; 84(5):952-960. PubMed ID: 29341245
[TBL] [Abstract][Full Text] [Related]
14. The impact of simvastatin on warfarin disposition and dose requirements.
Sconce EA; Khan TI; Daly AK; Wynne HA; Kamali F
J Thromb Haemost; 2006 Jun; 4(6):1422-4. PubMed ID: 16706996
[No Abstract] [Full Text] [Related]
15. A comparative study for detecting CYP3A induction by CYP3A probe drugs and endogenous markers in cynomolgus monkeys.
Tahara H; Watanabe M; Hasegawa M
Biopharm Drug Dispos; 2019 Feb; 40(2):81-93. PubMed ID: 30724384
[TBL] [Abstract][Full Text] [Related]
16. Pharmacokinetic Interaction of Rifampicin with Oral Versus Intravenous Anticancer Drugs: Challenges, Dilemmas and Paradoxical Effects Due to Multiple Mechanisms.
Srinivas NR
Drugs R D; 2016 Jun; 16(2):141-8. PubMed ID: 27098526
[TBL] [Abstract][Full Text] [Related]
17. Pharmacokinetics of Tecarfarin and Warfarin in Patients with Severe Chronic Kidney Disease.
Albrecht D; Turakhia MP; Ries D; Marbury T; Smith W; Dillon D; Milner PG; Midei MG
Thromb Haemost; 2017 Nov; 117(11):2026-2033. PubMed ID: 28933798
[TBL] [Abstract][Full Text] [Related]
18. The Effects of Weak and Strong CYP3A Induction by Rifampicin on the Pharmacokinetics of Five Progestins and Ethinylestradiol Compared to Midazolam.
Wiesinger H; Klein S; Rottmann A; Nowotny B; Riecke K; Gashaw I; Brudny-Klöppel M; Fricke R; Höchel J; Friedrich C
Clin Pharmacol Ther; 2020 Oct; 108(4):798-807. PubMed ID: 32275771
[TBL] [Abstract][Full Text] [Related]
19. Influence of coagulation factor, vitamin K epoxide reductase complex subunit 1, and cytochrome P450 2C9 gene polymorphisms on warfarin dose requirements.
Aquilante CL; Langaee TY; Lopez LM; Yarandi HN; Tromberg JS; Mohuczy D; Gaston KL; Waddell CD; Chirico MJ; Johnson JA
Clin Pharmacol Ther; 2006 Apr; 79(4):291-302. PubMed ID: 16580898
[TBL] [Abstract][Full Text] [Related]
20. Warfarin and bosentan interaction in a patient with pulmonary hypertension secondary to bilateral pulmonary emboli.
Spangler ML; Saxena S
Clin Ther; 2010 Jan; 32(1):53-6. PubMed ID: 20171411
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
